Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews
CONCLUSION: Statins have the most consistent evidence for the prevention of cardiovascular complications with a relative risk reduction of about 25% for MACE and 10% to 15% for mortality. The addition of ezetimibe, a PCSK9 inhibitor, or eicosapentaenoic acid ethyl ester to a statin provides additional MACE risk reduction but has no effect on all-cause mortality.PMID:37833094 | PMC:PMC10575662 | DOI:10.46747/cfp.6910701 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Nicolas Dugr é Adrienne J Lindblad Danielle Perry G Michael Allan Émélie Braschi Jamie Falk Liesbeth Froentjes Scott R Garrison Jessica E M Kirkwood Christina S Korownyk James P McCormack Samantha S Moe Allison Paige Jen Potter Betsy S Thomas Joey Ton Source Type: research
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care
CONCLUSION: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.PMID:37833089 | PMC:PMC10575658 | DOI:10.46747/cfp.6910675 (Source: Canadian Family Physician Medecin de Famille Canadien)
Source: Canadian Family Physician Medecin de Famille Canadien - October 13, 2023 Category: Primary Care Authors: Michael R Kolber Scott Klarenbach Michel Cauchon Mike Cotterill Loren Regier Raelene D Marceau Norah Duggan Rebecca Whitley Alex S Halme Tanis Poshtar G Michael Allan Christina S Korownyk Joey Ton Liesbeth Froentjes Samantha S Moe Danielle Perry Betsy S T Source Type: research
Characterization of Indian gut microbiome for B-vitamins production and its comparison with Chinese cohort
Br J Nutr. 2023 Oct 2:1-28. doi: 10.1017/S0007114523002179. Online ahead of print.ABSTRACTThe human gut microbiota can biosynthesize essential micronutrients such as B-vitamins, and is also known for its metabolic cooperative behaviour. The current study characterizes such B-vitamin biosynthesizers, their biosynthetic pathways, explores their prevalence and abundance, and examines how lifestyle or diet affects them in multiple Indian cohorts, and compares it with the Chinese cohort. To achieve this, publicly available fecal metagenome data of healthy individuals from multiple Indian (two urban and three tribal populations)...
Source: The British Journal of Nutrition - October 2, 2023 Category: Nutrition Authors: Nisha Chandel Pramod Rajaram Somvanshi Vivek Thakur Source Type: research
